Navigation Links
Make No Small Plans: M. D. Anderson Cancer Center Endeavors to Make Cancer History
Date:5/8/2009

ent Egyptian and Greek medicine and the modern advances that comprise the oncology field as it is known today.

Due to these early contributions and huge leaps in the understanding of cancer made by M. D. Anderson and its peer institutions over the decades, the five-year survival rate for all forms of cancer combined has risen to 66 percent, more than double what it was 50 years ago. An American diagnosed with cancer today is very likely to join the growing ranks of survivors. Even when not curable, more cancers are managed as effectively as other chronic, life-long diseases.

"I am fortunate that my life and career have spanned many of the major medical, technological and research developments presented in Making Cancer History," said John Mendelsohn, M. D., president of M. D. Anderson. "With remarkable truth and clarity, Jim has captured the stubborn spirit, heroic attempts, colossal setbacks and glittering achievements we have faced - as a nation and an institution - in cancer care and research. This is no dry institutional history, but a record of the will and courage to confront and conquer cancer."

From the Wild West to the Pink Palace

From radical surgery, the ability to harness the force of radiation to kill disease and the dawning of the age of chemotherapy up to the discovery of DNA and immunology, Olson explores the evolution of cancer treatment parallel to M. D. Anderson's own quest to bring scientific discoveries to the clinic as rapidly as possible.

Founded as the anchor of the now-renowned Texas Medical Center, the largest of its kind in the world, Olson credits its three presidents with forging M. D. Anderson's distinctive culture, ability to attract world-class specialists, commitment to innovation, multidisciplinary approach to patient care and leadership role in national policy.

Struck by the presence of Georgia Etowa Pink marble on a drive through
'/>"/>

SOURCE The University of Texas M. D. Anderson Cancer Center
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Veterans Administration Awards Small Business' $13 Million Contract to Digitize Veterans Health Records
2. Cardinal Health to Offer Allscripts Electronic Health Record to Solo and Small Physician Groups
3. Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
4. BlueChoice HealthPlan Adds Coverage for Young Adults and New Plans for Small Businesses
5. Exercise programs may improve symptoms in non-small cell lung cancer patients
6. Scope of Swine Flu Outbreak in Mexico Might Be Smaller Than Thought
7. Using a small stockpile of a secondary antiviral drug in a flu pandemic
8. Smallest full support heart assist device on trial at Northwestern Memorial
9. Good News for Tough Times: Small, Private University Responds to Todays Economic Challenges
10. Media invited to ACS Webinar on chemistry and entreprenuership and small/medium business
11. Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... An August 25 article ... surgeries conducted each year on teenagers, quoting a New York City-area plastic surgeon ... plastic surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known more familiarly to patients and ...
(Date:9/1/2015)... ... 01, 2015 , ... The Capillus82™ has been cleared by ... in adults, announces Miami-based medical device manufacturer, Capillus, LLC. FDA clearance substantiates the ... when used at home to combat hair loss. , “Following the success ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... therapy company, is pleased to announce their partnership with Apex Physical Therapy ... both groups to continue to provide kind, compassionate, and empathetic care to local ...
(Date:9/1/2015)... NY (PRWEB) , ... September 01, 2015 , ... From ... 86 children and teenagers, from ages 6-18. Calvary’s Camp Compass® has taken place at ... staff included 65 adult counselors, some of whom work for Calvary, and two junior ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... cure and prevent different malignancies. Some options for cancer treatment are available ... to which distinctive approach is necessary for effective treatment. Several molecules have ...
Breaking Medicine News(10 mins):Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 2Health News:ProRehab Physical Therapy Partnership with Apex Physical Therapy Now Official 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3
... live a happy married life beat stress better than those ... a best stress buster//. ,Popular perception is that single ... that being in a loving relationship makes it easier to ... online edition of Daily Mail. ,Psychologist Dr Roxane ...
... epidemic proportions, forcing changes in many aspects of that ... fleet of ambulances to cope with a sharp rise ... been introduced and new air ambulances will be remodeled ... equipped with heavy-duty stretchers, capable of carrying patients weighing ...
... are discovering that some foods and supplements do have an ... killer- the ‘big C’. At the 233rd national meeting of ... dozen research papers on this topic will be presented. ... show promise for preventing cancer of the esophagus, colon — ...
... to increase libido in women will hit the market soon. This ... by the European Medicines Agency. ,This patch could be ... the male hormone testosterone into the bloodstream. Intrinsa is intended for ... patch is similar to Viagra for men and is said to ...
... was conducted in all mental health units in England ... in mixed wards//. This is much against the government’s ... hospitals. ,The healthcare commission reports that 55% ... bathrooms with the opposite sex. This practice has resulted ...
... A combination of AZT, lamivudine, and nevirapine (AZT/3TC/NVP) taken ... month after delivery resulted in significantly reduced HIV levels ... found in the breast milk of women who were ... (Drug Resource Enhancement Against AIDS and Malnutrition) in Mozambique ...
Cached Medicine News:Health News:Emboldened Warriors-Cancer Fighting Foods 2Health News:Emboldened Warriors-Cancer Fighting Foods 3Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 2Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 3Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 4
(Date:9/1/2015)... 1, 2015 Nevro Corp. (NYSE: NVRO ... innovative evidence-based solutions for the treatment of chronic pain, ... response to the Patent Trial and Appeals Board (PTAB) ... review (IPR), filed by a unit of Boston Scientific ... Patent No. 8,359,102 (the ,102 patent). The ,102 patent is ...
(Date:9/1/2015)... and BRUSSELS , ... ) and UCB (Euronext Brussels: UCB) today announced ... effect of RomosozUmab Compared with Teriparatide in postmenopaUsal ... pReviously treated with bisphosphonatE therapy). The study (NCT01796301) ... difference in favor of romosozumab in the percent ...
(Date:9/1/2015)... , Sept. 1, 2015 Konica Minolta Medical ... Radiography (CR) system, designed to deliver enterprise level imaging ... the same Control Station as the Konica Minolta AeroDR ... an upgrade path from CR to DR. The SIGMA ... help improve workflow with unparalleled reliability and high capacity ...
Breaking Medicine Technology:Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Konica Minolta Launches New CR System with Low-Cost Upgrade Path to DR 2
... March 21, 2008, HOUSTON, March 3 ... new policies, a national alliance of,scientists, public health ... on a series of proposals designed to eliminate,continued ... of the four year initiative, Eliminating Disparities in,Clinical ...
... Significant Pain Relief with the 2.5 ... and 5 mg Doses Compared to ... (Nasdaq: ALXA ) announced today positive top-line,results from its ... patients with migraine headache. Migraine is a debilitating,yet common neurological ...
Cached Medicine Technology:EDICT Opens Public Comment Period for Clinical Trials Policy Recommendations 2Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 2Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 3Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 4Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 5Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 6Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 7Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 8
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: